BAYRY
Courtroom drama, now with more drama
Bayer’s stock took a hit after the U.S. Supreme Court appeared split in its review of the company’s fight over Roundup lawsuits. Translation: this is not the clean, decisive win Bayer was probably hoping for.
Why the market flinched
Roundup has been hanging over Bayer like a storm cloud for years, and every courtroom wrinkle matters. If the justices don’t give Bayer the legal relief it wants, the company could keep facing a long tail of claims and settlements — aka the kind of thing investors hate because it turns balance sheets into stress tests.
What you should watch next
- Whether the Court signals a path that helps Bayer narrow future claims
- Any fresh commentary on how much exposure the company could still face
- Whether investors treat this as a temporary wobble or another reminder that the Roundup saga is nowhere near retired
Big picture: Bayer doesn’t just need a business turnaround — it needs the legal headlights to stop swinging at it from every direction.